BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 2
• 3
• 4
• 5
• 6
• 7

• 

  Opinion

  Pharma Is Sitting on Hidden Cures. Find Your “Freda” To Unlock Them

  Had Pfizer’s Freda Lewis-Hall not stepped in, SpringWorks’ rare disease treatment may never have reached patients. Pharmas can act now to help find the next Gomekli.

  November 4, 2025

   · 

  4 min read

   · 

  Annette Bakker
• 

  Manufacturing

  Generic Drug and API Manufacturers Call for Onshoring Incentives

  Having seen Congress spend money to onshore semiconductor production, pharma groups are pushing for similar incentives for domestic drug manufacturing.

  November 4, 2025

   · 

  4 min read

   · 

  Nick Paul Taylor
• 

  Rare diseases

  UCB Wins First FDA Approval for Ultra-Rare Mitochondrial Disease

  Kygevvi is indicated for patients with thymidine kinase 2 deficiency whose symptoms arise by 12 years of age. The disease manifests as muscle weakness and can become life-threatening in severe instances.

  November 4, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Duchenne muscular dystrophy

  Sarepta’s DMD Exon-Skippers Fail Confirmatory Study, Stock Craters

  Sarepta nevertheless plans to push for full FDA approval of Vyondys 53 and Amondys 45 based on what it said are “encouraging trends” in efficacy.

  November 4, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Vertex’s New Products Dim as Analysts Eye Kidney Portfolio

  The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy.

  November 4, 2025

   · 

  5 min read

   · 

  Tristan Manalac
• 

  Job Trends

  BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces

  BioSpace has named 50 life sciences companies to its 2026 Best Places to Work list. AbbVie, Amneal Pharmaceuticals and BridgeBio executives share what makes their organizations special.

  November 4, 2025

   · 

  7 min read

   · 

  Angela Gabriel
• 

  Earnings

  Pfizer Fields Novo’s $10B Curveball, With Bourla Promising To Fight for Metsera

  Due to the litigation Pfizer filed Friday and Monday against Metsera, Novo Nordisk and the biotech’s lead shareholder, CEO Albert Bourla was limited in what he could say. But he said Pfizer was the best fit for Metsera.

  November 4, 2025

   · 

  5 min read

   · 

  Annalee Armstrong
• 

  Mergers & acquisitions

  Novo Ups Ante In Metsera Buyout Drama With $10B Offer, Beating Pfizer’s New Bid
  

  Both companies have submitted revised bids, with Novo’s coming in $1.9 billion higher than Pfizer’s.

  November 4, 2025

   · 

  1 min read

   · 

  Annalee Armstrong
• Press Releases

  Thryv Therapeutics to Participate in Upcoming 2025 Healthcare Investor Conferences

  November 4, 2025

   · 

  1 min read
• Press Releases

  New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization

  November 4, 2025

   · 

  16 min read